Peptide Unit Design for Targeted Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapeutics face challenges in uniformly inducing the intended immune response and are costly to produce, often leading to varied antibody induction and high production costs due to the inclusion of multiple epitopes.
Innovation Solution
A peptide unit comprising a B-cell epitope and a Th epitope, specifically designed to induce humoral immunity, is developed. This peptide unit is 23-71mer in length, includes a B-cell epitope as a fragment or mimotope of apolipoprotein B-100, and is optimized for easy synthesis and low production costs by linking multiple peptide units.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple epitopes are included in immunotherapeutics to induce comprehensive immune response, then the breadth of immune coverage is improved, but the production cost increases and manufacturing complexity worsens
Solution Approach 1:
The patent divides the immunotherapeutic into separate components: a core peptide containing the B-cell epitope (23-71mer) and optional separate Th epitope components. This segmentation allows for standardized production of the core peptide while enabling flexible combination with different Th epitopes to achieve comprehensive immune coverage without proportionally increasing manufacturing complexity
Solution Approach 2:
The patent extracts and focuses on the essential B-cell epitope component as the core immunotherapeutic agent. By identifying and isolating the minimal necessary elements (the B-cell epitope-containing peptide), the patent reduces manufacturing complexity and cost while maintaining effective immune induction capability
2Adaptability or versatility
If multiple epitopes are included in immunotherapeutics to induce comprehensive immune response, then the breadth of immune coverage is improved, but the uniformity of antibody induction deteriorates
Solution Approach 1:
By separating the B-cell epitope (core component) from Th epitopes (auxiliary components), the patent ensures that the core peptide produces uniform antibody induction while Th epitopes can be selectively added to expand immune coverage. This segmentation maintains manufacturing precision of the core component while achieving versatility through optional additions
Solution Approach 2:
The patent applies different functional qualities to different parts: the core peptide (23-71mer) is optimized for uniform B-cell activation and antibody induction, while separate Th epitope components provide localized T-cell help functionality. This local quality differentiation ensures uniformity where needed while providing versatility where beneficial
3Adaptability or versatility
If longer peptide sequences are used to include multiple epitopes, then the immune response breadth is improved, but the synthesis difficulty and production cost increase
Solution Approach 1:
The patent segments the immunotherapeutic into a core peptide (23-71mer containing B-cell epitope) and optional separate Th epitope components. This segmentation enables synthesis of the core component within a manageable size range that balances immune effectiveness with synthesis feasibility, while Th epitopes can be added separately to expand functionality without proportionally increasing synthesis complexity
Solution Approach 2:
The patent extracts the essential immunogenic component (B-cell epitope-containing peptide of 23-71mer) as the core therapeutic agent. By removing non-essential longer sequence elements and focusing on the minimal effective component, the patent reduces synthesis difficulty and production cost while maintaining effective immune response breadth
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively induces antibodies that specifically bind to the B-cell epitope, achieving targeted immune responses with reduced side effects and lower production costs, as demonstrated by significant weight loss and improved lipid metabolism in obesity treatment models.
Implementation Method 1
a peptide unit which is 23mer to 71mer in length, is recognized by CD4+ T-cells to induce a humoral immunity
Implementation Method 2
they induce antibody production through an antigen-antibody reaction in the body of a subject
Data Source
AI summary
Provided is a peptide provided herein includes at least one peptide unit, and the peptide unit may include at least one B-cell epitope, at least one Th epitope, and an appropriate number of auxiliary parts. The peptide unit is a portion designed to uniformly induce only the intended antibody while exhibiting a certain level of immunogenicity in the body of a subject. In addition, the peptide unit is designed with a relatively short length, and thus has the characteristics of easy synthesis and a low production cost. The peptide has properties suitable for use as an immunotherapeutic due to the characteristics of the peptide unit described above. In the present specification, the design principles of the peptide and the peptide unit are disclosed in detail.